higher incidence of cough (p ¼ 0.001) and hemoptysis (p < 0.0001) in the bevacizumab-based arm, pain in the pemetrexed arm (p ¼ 0.007), and alopecia in the other treatments arm (p < 0.0001) was observed during treatment. A significantly higher incidence of hemoptysis in the bevacizumab-based arm (p < 0.0001) and alopecia in the other treatments arm (p < 0.0001) was seen at the end of first-line treatment. Conclusion: Bevacizumab-based regimens resulted in improved treatment response and short-term survival rate, but not in improved OS. An increased, albeit acceptable, toxicity was also observed among bevacizumab-treated patients as compared to those treated with pemetrexed monotherapy.
Background: Patients with epidermal growth factor (EGFR)-mutant non-small cell lung cancer (NSCLC) represent a distinct treatment and prognostic subgroup, typically responding to treatment with tyrosinekinase inhibitors (TKIs) but also displaying a highly variable prognosis. We herein aimed to further investigate the potential value of EGFR genotype as a predictor of survival in EGFR-mutant NSCLC. Method:
The medical records of 68 patients with NSCLC and positive EGFR mutation status, who had been treated with EGFR-TKIs, were retrospectively reviewed. Demographic, clinicopathological features and EGFR mutation testing results of patients were correlated with survival. Result: (EGFR) exon 19 E746-A750 deletion and (EGFR) exon 21 L858R point mutation were the commonest EGFR mutations, observed in 58% and 24% of patients, respectively. Median progression-free survival (PFS) among patients with (EGFR) exon 21, 19 and 18/20 was 22.9, 13.9 and 4.7 months, respectively. Median overall survival (mOS) for the above subgroups was 25.1, 35.8 and 13.8 months, respectively. The presence of (EGFR) exon 21 L858R point mutation was correlated with reduced risk of disease recurrence as compared to (EGFR) 18/20 mutations (HR¼0,25, p¼0,018); patients with (EGFR) exon 19 mutations had reduced risk of death as compared to those with (EGFR) exon 18/20 mutations (HR¼0, 29, p¼0, 007) Background: Unlike common epidermal growth factor receptor gene (EGFR) mutations that confer sensitivity to tyrosine kinase inhibitors (TKIs) in nonesmall cell lung cancer (NSCLC), mutations in exon 20 of either EGFR or the human EGFR2 gene (HER2) are associated with insensitivity to EGFR-TKIs, with treatment options for patients with such mutations being limited. Method: Clinical characteristics, outcome of EGFR-TKI or nivolumab treatment, and the presence of coexisting mutations were reviewed for NSCLC patients with exon-20 mutations of EGFR or HER2 as detected by routine application of an ampliconbased next-generation sequencing panel. Result: Between July 2013 and June 2017, 206 patients with pathologically confirmed lung cancer were screened for genetic alterations including HER2 and EGFR mutations. Ten patients harbored HER2 exon-20 insertions (one of whom also carried an exon-19 deletion of EGFR), and 12 patients harbored EGFR exon-20 mutations. Five of the 13 patients with EGFR mutations were treated with EGFR-TKIs, two of whom manifested a partial response, two stable disease, and one progressive disease. Among the seven patients treated with nivolumab, one patient manifested a partial response, three stable disease, and three progressive disease, with most (86%) of these patients discontinuing treatment as a result of disease progression within 4 months. The H1047R mutation of PIK3CA detected in one patient was the only actionable mutation coexisting with the exon-20 mutations of EGFR or HER2. Conclusion: Potentially actionable mutations thus rarely coexist with exon-20 mutations of EGFR or HER2, and EGFR-TKIs and nivolumab show limited efficacy in patients with such exon-20 mutations. Keywords: EGFR, HER2, Nivolumab Background: Although nivolumab showed the significantly longer overall survival (OS) compared with standard second-line therapy using docetaxel for both squamous and non-squamous non-small cell lung cancer (NSCLC) based on two phase III randomized controlled trials, PD-L1 expression alone is not yet an adequate biomarker in treating NSCLC patients with nivolmab. This single institute retrospective study aimed to analyze which biomarker or pretreatment patients' status were more associated with outcomes in NSCLC patients treated with nivolumab. Method: We retrospectively reviewed the medical records of all patients with previously treated advanced NSCLC who received nivolumab between December 2015 and May 2016 in our institute. And we confirmed PD-L1 expression in the patients who were able to examine PD-L1 status. Multivariable logistic regression and Cox proportional hazards models were used to assess the impact of pretreatment PD-L1 expression, performance status (PS), and inflammation parameter (neutrophil-to-lymphocyte ratio (NLR)) on progression-free survival (PFS) and OS. The data cut off was on 31th October 2017. Result: A total of 66 patients were included in this analysis. Median age was 66 (range, 46e85) years old, 48 patients were men, 54 patients were non-squamous cell carcinoma, 57 patients had a smoking history, 15 patients had a PS of 2 or higher, 23 patients were NLR 4, and 10 patients were PD-L1 expression 50 and 19 patients were PD-L1 expression 1-49. As for pretreatment prognostic factors, multivariate analyses revealed that never smoker (hazard ratio (HR): 4.22, 95% confidence interval (CI): 1.23 -15.90), PS 2 (HR: 3.72, 95% CI: 1.80 -7.52), and no PD-L1 expression (HR: 2.03, 95% CI: 1.10 e 3.84) were significantly associated with poor PFS, and furthermore PS 2 (HR: 6.27, 95% CI: 2.72 -14.65) was independently associated with poor OS. Conclusion: PS is the better prognostic factor than NLR and PD-L1 expression in NSCLC patients treated with nivolumab. Keywords: nonsmall cell lung cancer, Nivolumab, prognostic factor October 2018 Abstracts S903
